November 2025 Corporate Overview

2 2 This presentation has been prepared by Centessa Pharmaceuticals plc (the “Company”) for informational purposes only and not for any other purpose. This presentation does not contain all the information that is or may be material to investors or potential investors and should not be considered as advice or a recommendation to investors or potential investors in respect of the holding, purchasing or selling of securities or other financial instruments and does not take into account any investor’s particular objectives, financial situation or needs. The communication of this presentation may be restricted by law; it is not intended for distribution to, or use by any person in, any jurisdiction where such distribution or use would be contrary to local law or regulation. This presentation is not directed to or intended for distribution, or transfer, either directly or indirectly to, or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, transfer, publication, availability or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction. This presentation may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements, including, without limitation, statements related to the Company’s ability to deliver impactful medicines to patients; the ability of our key executives to drive execution of the Company’s portfolio of programs; our asset-centric business model and the intended advantages and benefits thereof; research and clinical development plans; the scope, progress, results and costs of developing our product candidates or any other future product candidates; the development and therapeutic potential of our product candidates, including ORX750, ORX142, and ORX489; strategy; regulatory matters, including the timing and likelihood of success of obtaining approvals to initiate or continue clinical trials or market any products; the Company’s ability to successfully conduct its clinical development of ORX750 below the maximum exposure limit set by the U.S. Food and Drug Administration (“FDA”) or, in the event the Company plans to exceed the maximum exposure limit, the Company’s ability to successfully have the maximum exposure limit removed; enroll subjects in clinical trials; market size and commercial opportunity for our product candidates; and our anticipated cash runway. Words such as “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “ongoing,” “aim,” “seek,” and variations of these words or similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based on the beliefs of the Company's management as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events and are subject to known and unknown risks, including, without limitation, risks related to our ability to protect and maintain our intellectual property position; business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about the Company; risks inherent in developing products and technologies; future results from our ongoing and planned clinical trials; our ability to obtain adequate financing, including through our financing facility with Oxford Finance, to fund our planned clinical trials and other expenses; trends in the industry; the legal and regulatory framework for the industry, including the receipt and maintenance of clearances to conduct or continue clinical testing; the risk that any one or more of our product candidates will not be successfully developed and commercialized; the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies; and geo-political risks such as the Russia-Ukraine war, the conflicts in the Middle East, trade wars and imposition of tariffs and other risk factors contained in our filings with the U.S. Securities and Exchange Commission. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. The actual results may vary from the anticipated results and the variations may be material. These forward-looking statements should not be taken as forecasts or promises nor should they be taken as implying any indication, assurance or guarantee that the assumptions on which such forward looking statements have been made are correct or exhaustive or, in the case of the assumptions, fully stated in this presentation. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this presentation is given. All projections, valuations, market-size forecast (including patient population), statistical analyses and study design illustrations are provided for information purposes only. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in projections, valuations, market-size forecast, statistical analyses, study design events, conditions or circumstances on which any such statement is based, except as may be required by law. They may be based on subjective assessments and assumptions and may use one among alternative methodologies that produce different results and to the extent they are based on historical information, they should not be relied upon as an accurate prediction of future performance. This presentation discusses product candidates that are under clinical study, and which have not yet been approved for marketing by the FDA or any other regulatory agency. No representation or warranty, express or implied, is made as to the safety or effectiveness of these product candidates for the use for which such product candidates are being studied. The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of such products. Certain information contained in this presentation relates to or is based on studies, publications, surveys, estimates, forecasts, projections and other data obtained from third party sources and the Company’s own internal estimates and research. While we believe these third-party sources to be reliable as of the date of this presentation, we have not independently verified, and make no representation or warranty, express or implied, as to the adequacy, fairness, accuracy or completeness of, any information obtained from third party sources. Finally, while we believe our own internal research is reliable, such research has not been verified by any independent source. Disclaimer and forward looking statements

Centessa reported $349.0 million in cash, cash equivalents and investments as of September 30, 2025. Cash runway estimated into mid-2027. Potential best -in-class / first-in-class orexin receptor 2 (OX2R) agonist franchise Robust series of clinical milestones anticipated across OX2R agonist pipeline in 2026 Strong balance sheet Discovering and developing transformational medicines for patientsMISSION 3

ORX750 Phase 2a data in patients with Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2), and Idiopathic Hypersomnia (IH) in 2025 Registrational program planned for Q1 2026 ORX142 Phase 1 data in acutely sleep -deprived healthy volunteers in 2025 Patient studies planned for Q1 2026 ORX489 Advancing in IND -enabling studies Clinical studies planned for Q1 2026* 2025 Focused Execution 2026 Driving Momentum *Subject to IND clearance Anticipated milestonesOREXIN 4

Orexin agonists have the potential to transform the standard of care for individuals with sleep-wake, neurological, neurodegenerative and neuropsychiatric disorders 5

Wakefulness Cognition Orexin Dopamine (Ventral tegmental area) Serotonin (Raphe nuclei) Acetylcholine (Basal forebrain) Sources: Pizza, F et al., J Sleep Res 2022;31(4):e13665; Toor, B et al., Front Neurol Neurosci 2021;45:38 ; Ten-Blanco, M et al., Front Neuroendo 2023;69:101066; and, Yamamoto, H et al., PLoS One, 2022;17(7):e0271901. Norepinephrine (Locus coeruleus) Histamine (Tuberomammillary nucleus) Attention Mood Targeting a key signaling neuropeptide implicated in numerous therapeutic areasOREXIN 6

ORX750 for the treatment of NT1, NT2 and IH ORX142 for the treatment ofneurological and neurodegenerative disorders Earlier stage OX2R agonists and therapeutics for additional potential indications ORX489 for the treatment ofneuropsychiatric disorders Molecule hOX2R EC50 (nM) Selectivity vs. hOX1R Native ligand orexin-A (OXA)1 0.035 n/a ORX750 1 0.110 9,800x ORX142 2 0.069 13,000x ORX489 3 0.035 8,800x Fluorescent imaging plate reader (FLIPR) assay with Chinese hamster ovary (CHO) cells stably expressing human recombinant OX1R or OX2R. 1. Black et al., World Sleep 2023 Abstract. 2. Black et al., European Sleep Research Society 2024 Abstract. 3. Company data / presentations. OREXIN Potential best -in-class / first-in-class OX2R agonist therapeutics 7

ASSET DISEASE/CONDITION MECHANISM PRE -CLINICAL PHASE 1 PHASE 2 ORX750 Narcolepsy Type 1 (NT1) OXR2 Agonist ORX750 Narcolepsy Type 2 (NT2) OXR2 Agonist ORX750 Idiopathic Hypersomnia (IH) OXR2 Agonist ORX142 Neurological & Neurodegenerative Disorders OXR2 Agonist ORX489 Neuropsychiatric Disorders OXR2 Agonist Undisclosed Assets Undisclosed Orexin Pathway Broad and rapidly advancing OX2R agonist pipelineOREXIN 8

Candidate Selection Criteria for a Best -in-Class Profile • Highly potent and highly selective • Optimal predicted PK profile • Low predicted human doses • Fast onset of action OX2R agonist Orexin -A: Highly Validated Pathway Proprietary Structure Based Drug Design Medicinal Chemistry SAR * *SAR is Structure- Activity Relationship optimization. Pipeline of highly potent, selective OX2R agonists enabled by proprietary structural biology insights OREXIN 9

Expect to initiate registrational studies in Q1 2026 High unmet medical need in NT1, NT2 and IH ORX750 Highly potent, selective OX2R agonist Significant commercial opportunity as potential treatment for all three indications Phase 2a data from initial low dose cohorts demonstrate potential best -in-class profile across all three indications 1 1. As of the September 23, 2025 data cut-off date for the Phase 2a study of ORX750; Data are considered preliminary, as the study is ongoing Potential to redefine the standard of care for patients with sleep -wake disorders 10 ORX750

https://clinicaltrials.gov/study/NCT06752668 MWT and ESS are established registrational endpoints for EDS in sleep-wake disorders and weekly cataplexy rate is an established registration endpoint for cataplexy in NT1. *Measured by Narcolepsy Severity Scale (NSS) and Idiopathic Hypersomnia Severity Scale (IHSS). Evaluate safety, tolerability, and PK in NT1, NT2, and IH patients Efficacy assessment registrational endpoints: Maintenance of Wakefulness Test (MWT), Epworth Sleepiness Scale (ESS) , weekly cataplexy rate (NT1 patients only), and overall symptom improvement* Exploratory efficacy assessments will measure sleep, cognition, attention, memory, and general health …Expect to initiate registration program in Q1 2026 Generally favorable safety and tolerability profile Statistically significant, clinically meaningful and dose -dependent efficacy Dose escalation across ongoing and future cohorts with once-daily and split -dose regimens , enabled by Phase 1 data First robust demonstration of oral OX2R agonist addressing wakefulness needs of patients across NT1, NT2 and IH… CRYSTAL-1 Phase 2a study in NT1, NT2 and IHORX750 11

12 ORX750 has been observed to be generally well -tolerated at all doses tested across each indication with all treatment-emergent adverse events (TEAEs) being transient and mild to moderate in severity. 55 participants with NT1, NT2 and IH who have been dosed with ORX750 in the 2 -week crossover dose cohorts completed as of the data cut -off date The most common TEAEs ( ≥10%) across all completed NT1, NT2 and IH cohorts pollakiuria 51% insomnia 22% dizziness 13% headache 11% Data cutoff as of September 23, 2025; Data are considered preliminary, as the study is ongoing Demonstrated a generally favorable safety and tolerability profileORX750

Generally favorable safety and tolerability profile Clinically meaningful improvements across multiple efficacy measures Dose escalation across ongoing and future cohorts within a 4-week parallel design 1 MWT, Maintenance of Wakefulness Test; MSL, Mean Sleep Latency; ESS, Epworth Sleepiness Scale; PBO, Placebo; SE, Standard Error; MWT and ESS analysis used a linear mixed model to estimate the treatment effect with the Least Square Mean (LS Mean); WCR analysis used a generalized linear mixed model (Poisson) to estimate the incidence rate ratio. The incidence rate ratio was calculated by dividing the adjusted incidence of the ORX750 group with the adjusted incidence of the placebo group; As of the September 23, 2025 data cut-off date for the Phase 2a study of ORX750; Data are considered preliminary, as the study is ongoing; 1. Ongoing QD dose in 2 week crossover design 13 >20-minute change from baseline in MSL compared with placebo on MWT with 1.5 mg dose | p-value=0.0026, n=6 0 0.60.2 0.4 0.8 1.0 0.13 WCR Incidence Rate Ratio Relative to Placebo relative reduction in weekly cataplexy rate87% with 1.5 mg dose | p-value=0.0025, n=7 0 5 10 15 20 IM P R O V EM EN T 19.6 M e an E SS T o ta l S co re ( SE ) 5.1 18.7 1.5 mgPBO Baseline ESS Score achieved normative range with 1.5 mg dose | p-value=0.0001, n=7 Normative range ORX750 Achieved statistically significant, clinically meaningful and dose-dependent improvements: MWT, ESS and WCR NT1 50% of participants achieved >30 minutes in MSL on MWT Potential Best -in-Class Profile

Statistically significant and clinically meaningful improvements from baseline on multiple efficacy measures , including MSL on MWT with 2 mg dose | p-value =0.0213, n=17 NT2 IH MWT, Maintenance of Wakefulness Test; MSL, Mean Sleep Latency; ESS, Epworth Sleepiness Scale; PBO, Placebo; SE, Standard Error; MWT and ESS analysis used a linear mixed model to estimate the Least Square Mean (LS Mean); As of the September 23, 2025 data cut-off date for the Phase 2a study of ORX750; Data are considered preliminary, as the study is ongoing. ESS Score for NT2 achieved normative range with 4 mg dose | p-value= 0.0023, n=10 >10-minute change from baseline in MSL compared with placebo on MWT with 4 mg dose | p-value=0.0193, n=10 14 M e an E SS T o ta l S co re ( SE ) 0 5 10 15 20 IM P R O V EM EN T 17.3 8.1 15.9 4 mgPBO Baseline Normative range ORX750 Demonstrated clinically meaningful improvements on multiple efficacy measures; Data has the potential to establish ORX750 as the new standard of care for NT2 Generally favorable safety and tolerability profile Clinically meaningful improvements across multiple efficacy measures Dose escalation across ongoing and future cohorts within a 4-week parallel design Potential Best -in-Class / First -in-Class Profile

Innovative design with potential to enable well -powered and efficient data generation Optimal number of patients to allow efficient recruitment Potential for optimized dose selection Note: Study design for illustrative purposes only. Dosing started at 1.0 mg in NT1 and 2.0 mg in NT2 and IH once - daily 4-week placebo -controlled data at target doses Open-label extension study initiated ORX750 Randomized, double -blind, placebo -controlled basket study of ORX750 in patients with NT1, NT2, and IH ongoing 15 Randomization NT1X: n=8 (1:1) NT2X: n=12 (1:1) IHX: n=12 (1:1) Ongoing and Future Cohorts ORX750 Placebo Placebo ORX750 2 weeks 2 weeks MWT ESS MWT ESS 2 weeks ORX750 9 weeks Open Label Extension MWT ESS MWT ESS

EDS is excessive daytime sleepiness. Source of prevalent patient estimates: Acquavella et al., J Clin Sleep Med 2020; Saad et al., Sleep 2023; and Centessa market research. Source of diagnosed and treated patient estimates: Acquavella et al., J Clin Sleep Med 2020; Saad et al., Sleep 2023; and Ohayon et al. Sleep Med X. 2023. ORX750 Addressable Patient Population NT1, NT2, and IH NT1 ~80,000 Prevalent U.S. Patients • ~50,000 diagnosed and treated today • Characterized by EDS with cataplexy NT2 ~180,000 Prevalent U.S. Patients • ~100,000 diagnosed and treated today • Characterized by EDS (without cataplexy) IH ~360,000 Prevalent U.S. Patients • ~120,000 diagnosed and treated today • Characterized by EDS (without cataplexy), fatigue, sleep inertia ~270,000 Diagnosed and Treated U.S. Patients ~620,000 Prevalent U.S. Patients NT1, NT2, and IH represent large addressable patient populations 16 ORX750

Source: 1. Acquavella et al., J Clin Sleep Med 2020; Saad et al., Sleep 2023; and Centessa Market Research; 2. Prescribing information for current standard of care therapies; 3. FDA, “The Voice of the Patient: Narcolepsy” 2014; 4. Maski et al., J Clin sleep Med 2017; 5. American Association of Sleep Medicine (AASM) 2022. LARGE MARKET OPPORTUNITY Prevalent U.S. patients 1 HIGH UNMET NEED CURRENT APPROVED THERAPIES HAVE SIGNIFICANT LIMITATIONS ~620,000 3 INDICATIONS IN 1 EFFICIENT GO TO MARKET ORX750 HAS BEST-IN-CLASS POTENTIAL FOR THE TREATMENT OF NT1, NT2 AND IH CONCENTRATED CALL POINTS IN U.S.5 ~7,500 sleep specialists ~2,500 sleep centers • Slightly increased sleep onset latencies in patients as measured by MWT • Do not adequately address EDS, cataplexy or brain fog • Potential for significant side effects leading to treatment discontinuations • Challenges dealing with complex medication regimens~270,000 Diagnosed and treated U.S. patients 1 ADDRESSABLE PATIENT POPULATION IN NT1, NT2 AND IH Suboptimal Efficacy2 Poor Tolerability3 Flexible dosing supports potential to meet the needs of patients across 3 closely related indications Large, well defined commercial opportunity for ORX750 as potential treatment for NT1, NT2 and IH 17 ORX750

ORX142 Rapid onset of action and differentiated pharmacokinetics >13,000 -fold selectivity vs. hOX1R ; EC50 0.069 nM for hOX2R Planned for the treatment of neurological and neurodegenerative disorders ORX142 18 Generally well -tolerated at all doses tested with all AEs being self -limited and either mild or moderate intensity Improvements from baseline compared to placebo in mean sleep latency on the MWT at all doses tested Statistically significant Clinically meaningful Dose-dependent Phase 1 89 healthy adult volunteers Advancing pipeline molecule characterized by high potency and differentiated pharmacokinetics ORX142 As of the October 3, 2025 data cut-off date for the Phase 1 study of ORX142 in healthy volunteers. Data are considered preliminary, as the study is ongoing.

ORX750 Registrational program planned for Q1 2026 ORX142 Patient studies planned for Q1 2026 ORX489 Advancing in IND -enabling studies; Clinical studies planned for Q1 2026* 19*Subject to IND clearance Building a class -leading franchiseOREXIN

Centessa Pharmaceuticals plc 8-K